• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Viz.ai, NICO collaborate to improve intracerebral hemorrhage treatment

Viz.ai, NICO collaborate to improve intracerebral hemorrhage treatment

April 17, 2024 By Danielle Kirsh

viz.ai nico corporation logosViz.ai today announced a collaboration with NICO Corporation to help improve the lives of patients with intracerebral hemorrhages.

Intracerebral hemorrhage (ICH) is caused by bleeding in the brain tissue and is a life-threatening type of stroke. It accounts for up to 15% of all strokes and has high morbidity and mortality rates.

Viz-ai’s technology can help hospitals detect suspected diseases earlier and allow for accurate volume measurements of brain bleeds, which can be crucial for determining the severity of cases. NICO’s technology gives early and safe access to the brain with BrainPath and maximal evacuation of the clot using Myriad. The two companies’ technologies will increase efficiencies and enhance patient care.

“The results of the ENRICH trial have finally shown positive treatment data on one of the most costly and deadly diseases,” Viz.ai CEO Dr. Chris Mansi said in a news release. “We’re excited to collaborate with NICO, leveraging our broadly deployed AI platform to assist neurosurgeons in their decision making and improve patient outcomes post intracerebral hemorrhage.”

The results of the ENRICH trial showed that early minimally invasive parafascicular surgery intervention was safe and superior to guideline-based medical management alone, using NICO’s BrainPath and Myriad technology.

Viz.ai’s AI-powered ICH Plus module will allow hospitals and health systems to automate the process of identifying, labeling, and determining the volume of segmentable brain structures on non-contrast computed tomography images. According to the company, the technology can be incorporated seamlessly into the workflows of radiologists, neurologists, and neurosurgeons.

“The combination of our patented technologies, the collaboration with Viz.ai and the results of the ENRICH trial are transforming the way that ICH is treated,” NICO President and CEO Jim Pearson said. “The AI modules, Viz ICH and Viz ICH Plus, are a welcomed enhancement to patient care by leveraging AI-powered care coordination, getting patients the care they need, when they need it most.”

Filed Under: Artificial Intelligence (AI), Hospital Care Tagged With: NICO, Viz.ai

More recent news

  • Autonomix picks up key nerve ablation catheter patent
  • Affluent Medical can move to pivotal phase of artificial urinary sphincter study
  • Globus Medical announces $500M share repurchase program
  • Cook Medical warns of issue with angiographic catheter
  • Virtuoso Surgical reports first cases with robotic endoscopy system, plans FDA IDE submission

About Danielle Kirsh

Danielle Kirsh is an award-winning journalist and senior editor for Medical Design & Outsourcing, MassDevice, and Medical Tubing + Extrusion, and the founder of Women in Medtech and lead editor for Big 100. She received her bachelor's degree in broadcast journalism and mass communication from Norfolk State University and is pursuing her master's in global strategic communications at the University of Florida. You can connect with her on Twitter and LinkedIn, or email her at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy